Published on June 26, 2012 at 2:47 AM
NextBio and Cancer Care Institute (CCI) announced today a strategic
partnership aimed at furthering the adoption of genomics in the clinic.
The collaboration will facilitate use of the NextBio platform to
interpret genomic molecular data for oncology patients and streamline
the complete workflow for use of molecular data in a clinical setting.
"Cancer Care Institute cares for a very diverse group of patients of
many different races and ethnicities, so we often see findings and
trends that are not captured in the literature," said Morteza
Dowlatshahi, M.D., Medical Director of Cancer Care Institute. "NextBio
Clinical provides a powerful, easy-to-use way to interpret our patients'
genomic data to conduct research studies as well as identify optimal
treatments. We look forward to integrating NextBio into our daily
"The ability to positively impact the treatment for a patient by
understanding their individual genome and identifying actionable
variants by correlating the patient's data with thousands of similar
patients is truly rewarding," said Alpana Verma-Alag, M.D., Head of
Clinical Development at NextBio. "Using Big Data technologies, we can
now meaningfully interpret the molecular data from a person in a short
amount of time, which has phenomenal implications for translational
research and patient care."
"Our partnerships with Cancer Care Institute and other clinical centers
complement our long-time work with pharmaceutical and biotechnology
companies and research centers," said Saeid Akhtari, Co-Founder,
President, and Chief Executive Officer of NextBio. "It has always been
NextBio's goal to serve the full spectrum of life sciences research,
from the laboratory to translational research to the clinic, thus
enabling the latest advancements in genomics and other -omics research
to ultimately spread to patient benefits in a seamless manner."
Source: Cancer Care Institute